The stock of Edwards Lifesciences Corporation (NYSE:EW) last traded at $75.91, up 2.15% from the previous session.
Data from the available sources indicates that Edwards Lifesciences Corporation (NYSE:EW) is covered by 27 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $118.00 and a low of $73.00, we find $95.00. Given the previous closing price of $74.31, this indicates a potential upside of 27.84 percent. EW stock price is now -6.16% away from the 50-day moving average and -22.37% away from the 200-day moving average. The market capitalization of the company currently stands at $46.11B.
In total, 7 analysts have assigned it a hold rating, and 16 have given it a buy rating. Brokers who have rated the stock have averaged $92.51 as their price target over the next twelve months.
On October 26, 2022, Mizuho recently initiated its ‘Buy’ rating on the stock quoting a target price of $100, while ‘Barclays’ rates the stock as ‘Overweight’.
In other news, Chopra Daveen, CVP, Surgical Structural Heart sold 4,000 shares of the company’s stock on Nov 15. The stock was sold for $296,720 at an average price of $74.18. Upon completion of the transaction, the CVP, Surgical Structural Heart now directly owns 18,911 shares in the company, valued at $1.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 14, Chairman & CEO MUSSALLEM MICHAEL A sold 19,875 shares of the business’s stock. A total of $1,473,636 was realized by selling the stock at an average price of $74.15. This leaves the insider owning 157,353 shares of the company worth $11.94 million. Insiders disposed of 932,168 shares of company stock worth roughly $70.76 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EW stock. A new stake in Edwards Lifesciences Corporation shares was purchased by ARTISAN PARTNERS LIMITED PARTNERSHIP during the first quarter worth $72,324,000. MIROVA US LLC invested $59,472,000 in shares of EW during the first quarter. In the first quarter, PERSONAL CAPITAL ADVISORS CORP acquired a new stake in Edwards Lifesciences Corporation valued at approximately $40,705,000. GREAT WEST LIFE ASSURANCE CO /CAN/ acquired a new stake in EW for approximately $38,788,000. WOODLINE PARTNERS LP purchased a new stake in EW valued at around $32,481,000 in the second quarter. In total, there are 1,762 active investors with 84.70% ownership of the company’s stock.
With an opening price of $74.61 on Wednesday morning, Edwards Lifesciences Corporation (NYSE: EW) set off the trading day. During the past 12 months, Edwards Lifesciences Corporation has had a low of $67.13 and a high of $131.73. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.80, and a quick ratio of 3.00. The fifty day moving average price for EW is $80.53 and a two-hundred day moving average price translates $97.61 for the stock.
The latest earnings results from Edwards Lifesciences Corporation (NYSE: EW) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at $0.61, missing analysts’ expectations of $0.62 by -0.01. This compares to $0.54 EPS in the same period last year. The net profit margin was 27.20% and return on equity was 24.50% for EW. The company reported revenue of $1.32 billion for the quarter, compared to $1.31 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.67 percent. For the current quarter, analysts expect EW to generate $1.41B in revenue.
Edwards Lifesciences Corporation(EW) Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.